Asthma treatment

41. Datamonitor – May 19, 2008 GlaxoSmithKline’s Advair reduces exacerbations in COPD patients GlaxoSmithKline has reported that the use of its Advair Diskus 250/50 demonstrated a 30% reduction in exacerbations in patients with chronic obstructive pulmonary disease who have a history of exacerbations as compared with salmeterol alone. The randomized study of 797 patients was a replicate study which found that after a year of treatment, patients treated with Advair Diskus 250/50 had a 30% reduction in the rate of annual exacerbations compared to salmeterol ….. Datamonitor – October 12, 2006 GSK applies for expanded FDA approval of Advair UK-based GlaxoSmithKline has submitted a new drug application to the FDA to expand the labeling for Advair based on results from a study that showed a reduction in the risk of death from chronic obstructive pulmonary disease. COPD, or chronic obstructive pulmonary disease, is a complex lung disease that results in a progressive decline in lung function that is ultimately debilitating and life-threatening. Results of the study showed a 17. 5% reduction in risk of death from ….. wire (USA) – January 16, 2008 Efficacy and Familiarity are Key Reasons Physicians Prescribe GlaxoSmithKline’s Advair for the Treatment of Chronic Obstructive Pulmonary Disease and Asthma, AstraZeneca’s Symbicort is Gaining Favor Among Physicians for Use in the Treatment of the Diseases, According to New Reports from Decision Resources PRNewswire — Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Advair continues to be prescribed by a large percentage of primary care physicians as a first-line maintenance therapy for both chronic obstructive pulmonary disease (COPD) and asthma. Surveyed physicians indicated that efficacy and familiarity are the major reasons physicians choose Advair. Pulmonologists cite Advair’s ….. (MO) – March 7, 2006 Asthma drugs get stronger warnings Death risk increased for Advair, Serevent WASHINGTON – The asthma medication Advair and a related drug will bear stronger warnings of an increased risk of death associated with one of their ingredients. The revised warnings apply to Advair and Serevent, Food and Drug Administration spokeswoman Laura Alvey said Monday. Advair is GlaxoSmithKline Inc. ’s best-selling product, and Serevent is another of the British company’s drugs. The updated versions of the “black-box” warnings on ….. AFX Europe Focus – March 16, 2007 AFX Europe (Focus): GlaxoSmithKline’s Advair disappoints in smoker’s lung study LONDON (AFX) – GlaxoSmithKline PLC’s Advair, given in combination with Pfizer Inc’s Spiriva, failed to significantly reduce exacerbations in patients with the respiratory illness COPD, or smoker’s lung, a study found. Researchers in Canada conducted a study of 449 patients with the illness, which encompasses chronic bronchitis and emphysema. An exacerbation is a worsening of symptoms such as difficulty breathing. COPD sufferers are typically ….. AFX UK Focus – March 16, 2007 AFX UK (Focus): GlaxoSmithKline’s Advair disappoints in smoker’s lung study LONDON (AFX) – GlaxoSmithKline PLC’s Advair, given in combination with Pfizer Inc’s Spiriva, failed to significantly reduce exacerbations in patients with the respiratory illness COPD, or smoker’s lung, a study found. Researchers in Canada conducted a study of 449 patients with the illness, which encompasses chronic bronchitis and emphysema. An exacerbation is a worsening of symptoms such as difficulty breathing. COPD sufferers are typically ….. Datamonitor – March 17, 2008 GSK’s Advair reduces asthma-related hospitalization GlaxoSmithKline has reported that the company’s Advair Diskus was associated with fewer asthma-related hospitalizations and emergency department visits in pediatric patients when compared to the use of inhaled corticosteroids alone. This was an observational study evaluating the rates of asthma-related hospitalizations and emergency department (ED) visits in children four to 11 years of age with persistent asthma. To be considered in the analysis, the child had to have ….. Datamonitor – March 17, 2008 GSK’s Advair reduces asthma-related hospitalization GlaxoSmithKline has reported that the company’s Advair Diskus was associated with fewer asthma-related hospitalizations and emergency department visits in pediatric patients when compared to the use of inhaled corticosteroids alone. This was an observational study evaluating the rates of asthma-related hospitalizations and emergency department (ED) visits in children four to 11 years of age with persistent asthma. To be considered in the analysis, the child had to have ….. – May 2, 2007 Higher dose Advair questioned by FDA panel A U. S. panel says there is not enough evidence to show that higher doses of Advair help chronic obstructive pulmonary disease patients live longer. GlaxoSmithKline is asking the Food and Drug Administration to approve higher dose of Advair to treat patients with chronic obstructive pulmonary disease, or COPD, The Wall Street Journal said Wednesday. One study submitted to the FDA panel showed a 2. 6 percent improvement in survival over three years among patients receiving Advair. The ….. wire (USA) – July 21, 2006 Biopsy Study Shows Combination of Long-Acting Beta2-Agonist and Low Steroid Dose in Advair Diskus(R) 100/50mcg Maintains Control of Airway Inflammation, Study Supports National Institute of Health Guidelines for the Diagnosis and Management of Asthma PRNewswire — The largest biopsy study conducted to date demonstrates that a lower dose of an inhaled corticosteroid (ICS) with the addition of a long acting beta2-agonist (LABA) is as effective in maintaining control of airway inflammation as a medium-dose ICS alone in patients with moderate asthma. The study, published in the July issue of the Journal of Allergy and Clinical Immunology (JACI), compared Advair Diskus (fluticasone propionate and salmeterol) 100/50 mcg with fluticasone ….